Hematological Cancer Stem Cells: A New Target for Improved Immunotherapy

Strategic Insights -

Researchers at the Aristotle University of Thessaloniki have shed light on the characteristics of hematological cancer stem cells (HCSCs), a subpopulation of cells within hematological cancers that enhance malignancy and render treatment more challenging. By examining the existing literature, the study aimed to identify potential targets for improving immunotherapy clinical decisions. The findings suggest that uncovering the underlying mechanisms behind HCSCs' properties could lead to the development of new and alternative targets for therapy.

Key Takeaways:

  • HCSCs are a subpopulation of cells within hematological cancers that enhance malignancy and render therapy more challenging.
  • The study aimed to combine existing information and clinical evidence to assess and bring to the spotlight targets related to HCSCs for improving therapeutic interventions.
  • Potential targets for improving immunotherapy clinical decisions include stem cell transplantation (SCT), monoclonal antibodies (mAbs), cell therapies, cancer vaccines, and oncolytic viruses.
  • The research concluded that through the evaluation of the existing literature, new and alternative targets can be assessed for use in existing and novel immunotherapeutic interventions.
  • Authors of the study include Sotirios Charalampos Diamantoudis, Nikolaos Grigoriadis, Ioannis S. Vizirianakis, Androulla N. Miliotou, Eleftheria Galatou, Stergiani Telliou, and Konstantinos Sideris.
  • The study highlights the importance of understanding the underlying mechanisms behind HCSCs' properties to develop effective therapeutic strategies.

Statistics:

  • 2025: The year in which the study was conducted and published.
  • Biocell: The journal in which the study was published, with a contact address at: Tech Science Press, 871 Coronado Center Dr, Suite 200, Henderson, NV 89052, USA.
  • The study has been peer-reviewed.
  • 18: The number of authors contributing to the study, including Sotirios Charalampos Diamantoudis, Nikolaos Grigoriadis, Ioannis S. Vizirianakis, Androulla N. Miliotou, Eleftheria Galatou, Stergiani Telliou, and Konstantinos Sideris.

Sources:

  • NewsRx. Findings from Aristotle University of Thessaloniki Update Understanding of Cancer Gene Therapy (Assessing the Hematological Cancer Stem Cell Landscape To Improve Immunotherapy Clinical Decisions). Vaccine Weekly. October 15, 2025; p 68.
  • Biocell, 2025.